NCT03434769View on ClinicalTrials.gov

AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 9, 2018

Primary Completion Date

March 1, 2023

Study Completion Date

February 29, 2036

Conditions
Non-Hodgkin Lymphoma
Interventions
DRUG

Cyclophosphamide

Cyclophosphamide 60mg/Kg on day -6

DRUG

Fludarabine

Fludarabine 25mg/m\^2 IV on days -5 to -3

BIOLOGICAL

CAR-T Cells

"Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0~Level -1 (1 x 105 cells/kg)~Level 1 \[Starting dose\] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)"

Trial Locations (2)

44106

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Benjamin Tomlinson

OTHER